详文均见于”最近进展”（除非另有说明）; 同一文章可能见于本节内不同分类
Full articles can be found under “Recent Progress” unless specified; same reports may be classified under different categories in this section
乳腺癌 Breast Cancer
12/31/2023: 新辅助化疗是否可以免去乳腺癌患者的局部淋巴结照射 Can regional lymph node irradiation be avoided in breast cancer patients following neoadjuvant chemotherapy
12/9/2023: Tucatinib 和 Trastuzumab Emtansine 治疗 HER2 阳性转移性乳腺癌 Combination of Tucatinib and Trastuzumab Emtansine for HER2+ breast cancer with brain metastases
12/3/2023: Datopotamab deruxtecan治疗ER+/HER2- 晚期乳腺癌 Datopotamab deruxtecan for ER+/HER2- advanced stage breast caner
11/26/2023: IDE161 用于治疗晚期或转移性 BRCA1/2 突变雌激素受体+ 乳腺癌 IDE161 for advanced or metastatic BRCA1/2/ER-positive breast cancer
11/12/2023: 从母乳中检测早期乳腺癌 Identifying circulating tumor DNA in breast milk
11/5/2023: 绝经前双侧卵巢切除术对身体衰老和慢性疾病的长期影响 Impact of premenopausal bilateral oophorectomy on physical aging and chronic medical conditions
11/4/2023: 九周相对于一年曲妥珠单抗治疗早期HER 2 阳性乳腺癌：10 年随访结果 Nine-week versus one-year trastuzumab for early HER2–positive breast cancer: 10-year update
9/9/2023: PHERGain 试验评估HER2[+]早期乳腺癌化疗降阶梯治疗 PHERGain trail evaluating chemotherapy de-escalation in HER2[+] early breast cancer
8/27/2023: 重复活检对三阴性乳腺癌患者的 HER2 低状态的影响 HER2-low status on repeated biopsies in triple-negative breast cancer
8/20/2023: Ribociclib 和内分泌治疗作为 HR+/HER2- 早期乳腺癌的辅助治疗 Ribociclib plus endocrine therapy as adjuvant treatment in HR+/HER2- early breast cancer
8/12/2023: 第一线或第二线CDK4/6 抑制剂治疗 HR+/HER2- 晚期乳腺癌 First- vs second-line CDK4/6 inhibitor in advanced ER+/HER2- breast cancer
8/12/2023: 在哌柏西利的治疗出现进展后继续维持哌柏西利+二线内分泌治疗并没有改善无进展生存期 Continued maintenance of Palbociclib plus second-line endocrine therapy after progression on Palbociclib did not improve progression-free survival
6/11/2023: 他莫昔芬对三阴性乳腺癌的治疗作用 Tamoxifen in triple-negative breast cancer
5/14/2023: 乳腺癌前哨淋巴结阳性后的腋窝放疗或手术：AMAROS 试验的 10 年结果 Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-year Results of the AMAROS trial
5/6/2023: 早期可手术乳腺癌的含蒽环类药物和含紫杉类药物的化疗：来自 86 项随机试验的 100,000 名的荟萃分析 Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a meta-analysis of 100,000 women from 86 randomized trials
3/19/2023: Camizestrant 改善ER+/HER2- 晚期乳腺癌的无进展生存期 Camizestrant improved PFS in advanced ER+/HER2- breast cancer
3/11/2023: 辅助紫杉醇和曲妥珠单抗治疗淋巴结阴性/HER2 阳性乳腺癌：10 年分析 Adjuvant paclitaxel and trastuzumab for node-negative/HER2-positive breast cancer: final 10-year analysis
3/4/2023: Tucatinib 联合曲妥珠单抗和卡培他滨治疗既往治疗过的 HER2 阳性转移性乳腺癌脑转移 Tucatinib in combination with trastuzumab and capecitabine for HER2-Positive breast cancer with brain metastases
2/25/2023: 对早期乳腺癌进行或不进行放疗的保乳手术 Breast-conserving surgery with or without radiation in early breast cancer
2/18/2023: 新辅助 T-DXd 用于 HER2-低表达的 乳腺癌 Neoadjuvant T-DXd in HER2-low breast cancer
1/8/2023: Patritumab deruxtecan 在表达 HER3 的转移性乳腺癌患者中的研究结果 Results of a clinical trial using Patritumab deruxtecan in HER3-expressing metastatic breast cancer
肺癌 Lung cancer
12/30/2023: 奥希替尼联合或不联合化疗对EGFR突变的晚期非小细胞肺癌的中枢神经系统疗效 CNS efficacy of osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC
12/16/2023: 新辅助化疗加纳武单抗联合或不联合伊匹单抗治疗可手术非小细胞肺癌 Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable NSCLC
11/18/2023: 一线治疗RET 融合阳性非小细胞肺癌: Selpercatinib 相对于化疗+/- pembrolizumab First line selpercatinib vs chemotherapy +/- pembrolizumab in RET fusion-positive NSCLC
11/11/2023: Patritumab Deruxtecan 用于EGFR突变的治疗后进展的非小细胞肺癌 (NSCLC) Patritumab Deruxtecan in EGFR-mutated non-small-cell lung cancer (NSCLC) that progressed after target and chemotherapy
10/22/2023: 检查点抑制剂对 EGFR 突变肺癌疾病进展后的疗效Checkpoint inhibitor offered limited benefit in EGFR-mutated lung cancer following disease progression
9/16/2023: 针对有肺癌家族史和重度吸烟史检测早期肺癌: 来自台湾的报导 Screening lung cancer in population with heavy-smoking or lung cancer family history: A report from Taiwan
6/25/2023: Cemiplimab持久改善非小细胞肺癌生存率 Durable improvement in overall survival with Cemiplimab in non-small cell lung cancer (NSCLC)
6/24/2023: Tarlatamab, 一种首创的靶向双特异性 T 细胞接合剂，治疗复发性小细胞肺癌 Tarlatamab, a first-in-class bispecific T-cell engager, in treating recurrent small-cell lung cancer (SCLC)
6/10/2023: 奥希替尼辅助治疗肿瘤切除后 IB–IIIA 期非小细胞肺癌 Osimertinib as adjuvant therapy in stage IB–IIIA EGFR mutation positive NSCLC
3/26/2023: 新的ROS1 抑制剂对难治性实体瘤有响应 A new ROS1 inhibitor generated responses in refractory solid tumors
2/19/2023: Sotorasib 对比地西紫杉醇治疗 KRASG12C 突变非小细胞肺癌 Sotorasib v Docetaxel in KRASG12C mutant Non-small cell lung cancer (NSCLC)
1/22/2023: Atezolizumab 加贝伐单抗作为一线治疗具有高肿瘤突变负担的转移性非鳞状非小细胞肺癌 Atezolizumab plus bevacizumab as first-line therapy for metastatic non-squamous NSCLC with high tumor mutation burden
结直肠癌 Colorectal cancer
9/24/2023: 帕尼单抗相比于贝伐珠单抗联合标准一线化疗治疗RAS 野生型左侧转移性结直肠癌 Panitumumab vs bevacizumab plus standard first-line chemotherapy in RAS wild-type, left-sided metastatic colorectal cancer
7/23/2023: FOLFOX 在局部晚期直肠癌新辅助治疗并不劣于放化疗 FOLFOX was non-inferior to chemoradiation in rectal cancer
7/23/2023: 根据直肠癌风险确定新辅助放化疗 Risk-adapted neoadjuvant chemoradiation in rectal cancer
7/22/2023: CGX1321 联合或不联合 Pembrolizumab 对胃肠道癌症的I期试验 CGX1321 with or without pembrolizumab in GI cancers
7/1/2023: Regorafenib, Ipilimumab 和 Nivolumab 用于治疗微卫星稳定结直肠癌 Regorafenib, Ipilimumab and Nivolumab in treating microsatellite stable colorectal cancer
6/3/2023: 2023 年NCCN 肿瘤学临床指南更新: 结直肠癌/尿路上皮癌 NCCN practice guideline updates for 2023: colorectal and uroepithelial cancers
5/7/2023: TLR9 激活剂 pixatimod 与 nivolumab 联合治疗微卫星稳定的转移性实体瘤 TLR9 activator in combination with nivolumab in microsatellite stable metastatic solid tumors
2/6/2023: 炎症生物标志物与 III 期结肠癌患者生存的关联 Association of inflammatory biomarkers and the survival of stage III colon cancer
1/21/2023: FDA加速批准 tucatinib与曲妥珠单抗联合用于 RAS 野生型 HER2 阳性晚期结直肠癌 FDA approved tucatinib in combination with Herceptin in wild type RAS and HER2-positive advanced stage colorectal cancer
1/15/2023: Adagrasib 联合或不联合西妥昔单抗治疗 KRAS G12C 突变结直肠癌 Adagrasib alone or plus cetuximab in colorectal cancer with mutated KRAS G12C
胰腺癌 Pancreatic cancer
9/10/2023: NAPOLI-3: 第一线治疗转移性胰腺导管腺癌的III 期研究 NAPOLI-3: a randomized phase III study in treatment-naïve metastatic pancreatic ductal cancer
7/9/2023: 微创切除早期胰腺癌不亚于开腹远端切除胰腺 Minimally invasive distal pancreatectomy noninferior to open surgery for early-stage pancreatic cancer
5/13/2023: 个体化 RNA 新抗原疫苗可刺激胰腺癌中的 T 细胞 Personalized RNA neoantigen vaccine can stimulate T-cells in pancreatic cancer
胃/胃食管交界处腺癌 Gastric/gastroesophageal junction (GEJ) tumor
12/10/2023: 围手术期 Atezolizumab 加氟尿嘧啶, 亚叶酸, 奥沙利铂和多西他赛治疗可切除食管胃腺癌 Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric adenocarcinoma
12/2/2023: Domvanalimab, zimberelimab 和 FOLFOX 一线治疗晚期胃食管癌 Combination of domvanalimab, zimberelimab and FOLFOX as first line treatment for advanced gastric, GE junction and esophageal cancer
11/25/2023: 派姆单抗加化疗与安慰剂加化疗治疗 HER2 阴性晚期胃癌的比较 A randomized study to compare pembrolizumab plus chemo versus placebo plus chemo in HER2-negative advanced gastric cancer
9/30/2023: 第一线瑞戈非尼联合纳武单抗和化疗治疗晚期食管癌, 胃癌或胃食管交界癌 First-line regorafenib with nivolumab and chemotherapy in advanced esophageal, gastric or GEJ junction cancer
3/26/2023: ASCO对晚期胃食管癌的免疫/靶向第一线治疗的指南 ASCO guideline towards the firs-line immunotherapy and target therapy for advanced gastric and esophageal cancer
3/5/2023: 靶向CLDN18.2 的zolbetuximab加上化疗有利于不可切除或转移性胃或胃食管交界处腺癌 Zolbetuximab （targeting CLDN18.2） plus chemotherapy benefited patients with unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
胆道癌 Biliary tract cancer
9/3/2023: Zanidatamab 治疗 HER2 扩增, 局部晚期或转移性胆道癌 Zanidatamab for HER2-amplified locally-advanced or metastatic biliary tract cancer
7/15/2023: Erdafitinib 相对于化疗治疗患有选择性成纤维细胞生长因子受体改变的晚期尿路上皮癌 Erdafitinib vs. chemotherapy in advanced urothelial cell cancer with selective fibroblast growth factor receptor alterations
5/21/2023: 贝伐珠单抗联合化疗作为第一线治疗晚期胆道癌 Bevacizumab in combination with chemotherapy as first line for advanced biliary tract cancer
3/18/2023: 氨基酸转运蛋白抑制剂,Nanvuranlat，治疗晚期难治性胆道癌 Nanvuranlat, an L-type amino acid transporter inhibitor, for advanced refractory biliary tract cancer
胃肠胰神经内分泌肿瘤 Gastroenteropancreatic neuroendocrine tumors
12/23/2023: 转移性高分化胃肠胰神经内分泌肿瘤的治疗：ASCO 指南 Systemic therapy for tumor control in metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: ASCO guideline尿路上皮癌 Urothelial cancer
7/15/2023: Erdafitinib 相对于化疗治疗患有选择性成纤维细胞生长因子受体改变的晚期尿路上皮癌 Erdafitinib vs. chemotherapy in advanced urothelial cell cancer with selective fibroblast growth factor receptor alterations
6/3/2023: 2023 年NCCN 肿瘤学临床指南更新: 结直肠癌/尿路上皮癌 NCCN practice guideline updates for 2023: colorectal and uroepithelial cancers
2/26/2023: 抗体-药物偶联物（Enfortumab Vedotin*） 加 Pembrolizumab 治疗晚期尿路上皮癌 Antibody-drug conjugate （Enfortumab Vedotin* and pembrolizumab for advanced urothelial cancer
前列腺癌 Prostate cancer
9/23/2023: PectaSol-C modified citrus pectin治疗非转移性生化复发性前列腺癌 PectaSol-C modified citrus pectin (P-MCP) in non-metastatic biochemically relapsed prostate cancer
7/29/2023: 双相雄激素治疗随后雄激素受体抑制序贯治疗前列腺癌 Bipolar androgen therapy in sequence with androgen receptor blockade in prostate cancer
5/20/2023: 新辅助 enoblituzumab用于局限性前列腺癌的 Neoadjuvant enoblituzumab in locally advanced prostate cancer
4/23/2023: 阿比特龙和奥拉帕尼对相对于阿比特龙作为转移性去势抵抗性前列腺癌的一线疗法 First line abiraterone plus olaparib vs abiraterone/placebo in metastatic castration-resistant prostate cancer
4/15/2023: 睾酮抑制加恩杂鲁胺对比睾酮抑制加标准抗雄激素治疗转移性前列腺癌 Enzalutamide or standard antiandrogen therapy plus testosterone suppression in metastatic prostate cancer
4/8/2023: Talazoparib 联合 enzalutamide作为转移性去势抵抗性前列腺癌的一线治疗 Talazoparib in combination with enzalutamide as first-line therapy for metastatic castration-resistant prostate cancer
尿路上皮癌 Urothelial carcinoma
12/24/2023: Enfortumab vedotin (EV) 联合派姆单抗相比于化疗第一线治疗局部晚期转移性尿路上皮癌 Enfortumab vedotin in combination with pembrolizumab vs chemotherapy for untreated locally advanced metastatic urothelial carcinoma
膀胱癌 Bladder cancer
8/5/2023: 膀胱保留的根治性剂量放疗相对于膀胱切除术治疗非转移性膀胱癌 Bladder-sparing treatment with radical dose radiation versus radical cystectomy in non-metastatic bladder cancer
肾癌 Renal cancer
4/30/2023: CAR-T治疗晚期或转移性透明细胞肾细胞癌的I期临床试验 CAR-T cell therapy in a phase I trial for advanced/metastatic renal cell carcinoma
4/22/2023: Belzutifan 联合卡博替尼用于接受过免疫治疗的晚期透明细胞肾癌 Belzutifan plus cabozantinib for advanced clear-cell renal cell cancer previously treated with immunotherapy
卵巢癌 Ovarian cancer
10/1/2023: 晚期卵巢癌患者的细胞减灭手术+/-腹腔热腹化疗: 10 年随访的生存结果 Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer: 10-year follow-up of overall survival
9/2/2023: 奥拉帕尼新辅助治疗 BRCA 突变卵巢癌患者的初步研究 Pilot study of neoadjuvant Olaparib in ovarian cancer patients with BRCA mutation
8/13/2023: 第一线治疗无肿瘤 BRCA1/2 突变的晚期卵巢癌后给予维持 durvalumab, 贝伐单抗和奥拉帕尼 Maintenance durvalumab, bevacizumab and olaparib following first-line treatment of BRCA1/2-free advanced ovarian cancer patients without tumor BRCA1/2 mutations
6/4/2023: Pembrolizumab 联合化疗治疗晚期子宫内膜癌 Pembrolizumab in combination for advanced endometrial cancer
4/1/2023: 奥拉帕尼维持治疗相比于与安慰剂对卵巢癌的总生存期 Olaparib maintenance vs placebo in overall survival among ovarian cancer
子宫内膜癌 Endometrial cancer
7/30/2023: 野生型 TP53晚期子宫内膜癌患者selinexor 维持疗法的长期随访 Long-term follow-up of Selinexor as maintenance therapy in wild-type TP53 advanced endometrial cancer
7/8/2023: 晚期子宫内膜癌化疗添加放疗并没有改善生存率 Adding radiation to chemotherapy not improving survival in advanced endometrial cancer
6/4/2023: Pembrolizumab 联合化疗治疗晚期子宫内膜癌 Pembrolizumab in combination for advanced endometrial cancer
4/9/2023: PD-1抑制剂 Dostarlimab 治疗原发性晚期或复发性子宫内膜癌 PD-1 inhibitor Dostarlimab in primary advanced or recurrent endometrial cancer
宫颈癌 Cervical cancer
7/2/2023: 化疗加 pembrolizumab (派姆单抗) 提高晚期宫颈癌的生存率 Pembrolizumab added to chemotherapy improves survival in advanced cervical cancer黑色素瘤 Melanoma
5/28/2023: 地中海饮食与晚期黑色素瘤免疫治疗结果的关联 Association of Mediterran diet with outcome of immune check-point blockade in advanced melanoma
5/27/2023: 个体化mRNA癌症疫苗联合帕博利珠单抗用于切除的高危黑色素瘤 Personalized mRNA vaccine in combination with pembrolizumab in resected high-risk melanoma
黑色素瘤 Melanoma
12/17/2023: 个性化 mRNA 癌症疫苗与pembrolizumab联合用于黑色素瘤辅助治疗 Personalized mRNA vaccine in combination with pembrolizumab in melanoma adjuvant therapy
10/8/2023: FDA 批准melphalan作为葡萄膜黑色素瘤的肝脏定向治疗 FDA approves melphalan as a liver-directed treatment for uveal melanoma
5/27/2023: 个体化mRNA癌症疫苗联合帕博利珠单抗用于切除的高危黑色素瘤 Personalized mRNA vaccine in combination with pembrolizumab in resected high-risk melanoma
4/16/2023: 鞘内注射纳武单抗治疗黑色素瘤软脑膜疾病 Intrathecal administration of nivolumab for leptomeningeal disease in melanoma patients
肉瘤 Sarcoma
1/29/2023: ctDNA分析相关于 ripretinib 与舒尼替尼在胃肠道间质瘤的疗效 ctDNA analysis in relationship to efficacy of ripretinib vs sunitinib in GIST
脑瘤 Brain Tumor
7/16/2023: 植入式超声装置打开血脑屏障输送白蛋白结合紫杉醇治疗复发性胶质母细胞瘤 Opening blood-brain barrier with an implantable ultrasound device for delivery of albumin-bound paclitaxel in recurrent glioblastoma
淋巴瘤 Small lymphocytic lymphoma
11/19/2023: 苯达莫司汀治疗对接受嵌合抗原受体 T 细胞 (CAR-T) 治疗的大 B 细胞淋巴瘤预后产生负面影响 Negative impact of bendamustine on CAR-T therapy in diffuse large B-cell lymphoma (DLBCL)
10/31/2023: 高剂量甲氨蝶呤是否可以作为高危性 B 细胞淋巴瘤的中枢神经系统预防 Is high-dose methotrexate as CNS prophylaxis effective in high-risk B-cell lymphoma
10/14/2023: Pirtobrutinib用于共价 BTK 抑制剂后治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤 Pirtobrutini used after covalent BTK inhibitors in CLL/SLL
8/16/2023: 固定疗程 venetoclax 加 obinutuzumab 治疗老年慢性淋巴细胞白血病(CLL)患者的长期结果 Long-term results of fixed-duration venetoclax and obinutuzumab in elderly patients with CLL
8/6/2023: FDA 加速批准 epcoritab-bysp 治疗复发或难治性弥漫性大 B 细胞淋巴瘤 FDA granted accelerated approval to epcoritab-bysp for relapsed or refractory diffuse large B-cell lymphoma not otherwise specified
6/17/2023: FDA 批准 Glofitamab 用于复发/难治性弥漫性大 B 细胞淋巴瘤 (DLBCL) FDA granted accelerated approval of Glofitamab for recurrent/refractory DLBCL
4/29/2023: FDA 批准 polatuzumab vedotin-piiq 用于先前未治疗的弥漫性大 B 细胞/高级别 B 细胞淋巴瘤 FDA has approved polatuzumab vedotin-piiq in untreated diffuse large B-cell lymphoma and high-grade B-cell lymphpma
4/2/2023: 循环肿瘤 DNA 分析用于脑淋巴瘤检测, 风险分层和分类 Circulating DNA analyses for detection, risk stratification and classification of brain lymphoma
1/28/2023: Zanubrutinib用于慢性淋巴细胞白血病/小淋巴细胞淋巴瘤 Zanubrutinib for chronic lymphocytic leukemia/small lymphocytic lymphoma
多发性骨髓瘤 Multi[le myeloma
9/17/2023: Mezigdomide联合地塞米松治疗复发性和难治性多发性骨髓瘤 Mezigdomide in combination with dexamethasone in relapsed and refractory multiple myeloma
2/12/2023: Talquetamab，用于多发性骨髓瘤的 T 细胞重定向双特异性抗体 Talquetamab，A T-cell-redirecting bispecific antibody for multiple myeloma
肿瘤生物学和治疗/诊断新进展 Tumor biology & New treatment/diagnosis progress
12/17/2023: 个性化 mRNA 癌症疫苗与pembrolizumab联合用于黑色素瘤辅助治疗 Personalized mRNA vaccine in combination with pembrolizumab in melanoma adjuvant therapy
12/2/2023: Domvanalimab, zimberelimab 和 FOLFOX 一线治疗晚期胃食管癌 Combination of domvanalimab, zimberelimab and FOLFOX as first line treatment for advanced gastric, GE junction and esophageal cancer
11/12/2023: 从母乳中检测早期乳腺癌 Identifying circulating tumor DNA in breast milk
8/26/2023: Scintix 生物引导放射治疗癌症 Scintix biology-guided cancer radiotherapy
7/22/2023: CGX1321 联合或不联合 Pembrolizumab 对胃肠道癌症的 I 期试验 CGX1321 with or without pembrolizumab in GI cancers
7/16/2023: 植入式超声装置打开血脑屏障输送白蛋白结合紫杉醇治疗复发性胶质母细胞瘤 Opening blood-brain barrier with an implantable ultrasound device for delivery of albumin-bound paclitaxel in recurrent glioblastoma
6/18/2023: 紫外线辐射诱导皮肤中的树突状细胞白血病转化 Ultraviolet radiation and dendritic cell leukemic cell transformation in the skin
5/28/2023: 地中海饮食与晚期黑色素瘤免疫治疗结果的关联 Association of Mediterran diet with outcome of immune check-point blockade in advanced melanoma
5/13/2023: 个体化 RNA 新抗原疫苗可刺激胰腺癌中的 T 细胞 Personalized RNA neoantigen vaccine can stimulate T-cells in pancreatic cancer
5/7/2023: TLR9 激活剂 pixatimod 与 nivolumab 联合治疗微卫星稳定的转移性实体瘤 TLR9 activator in combination with nivolumab in microsatellite stable metastatic solid tumors
3/26/2023: 新的ROS1 抑制剂对难治性实体瘤有响应 A new ROS1 inhibitor generated responses in refractory solid tumors
1/14/2023: 针对 MAGE-A4+ 的自体 T 细胞疗法治疗HLA-A*02+实体癌患者 Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients
1/8/2023: Patritumab deruxtecan 在表达 HER3 的转移性乳腺癌患者中的研究结果 Results of a clinical trial using Patritumab deruxtecan in HER3-expressing metastatic breast cancer
1/1/2023: 第一个MYC 靶向疗法Omomyc完成 I 期临床试验 The first MYC-targeted inhibitor completed phase I trial
流行病学 Epidemiology
10/7/2023: 前瞻性队列研究早期血液检测多种癌症Prospective cohort study for multicancer early detection via blood-based tests
9/16/2023: 针对有肺癌家族史和重度吸烟史检测早期肺癌: 来自台湾的报导 Screening lung cancer in population with heavy-smoking or lung cancer family history: A report from Taiwan
副作用 Side-effects
11/5/2023: 绝经前双侧卵巢切除术对身体衰老和慢性疾病的长期影响Impact of premenopausal bilateral oophorectomy on physical aging and chronic medical conditions
3/12/2023: 饮食干预以减少淋巴瘤幸存者的疲劳: 可行性试点研究的结果 Food intervention to improve fatigue in lymphoma survivors: results of a Feasibility Pilot Study
2/11/2023: 服用Ibrutinib而有心脏毒性患者的心血管磁共振表现 Cardiovascular MRI of patients with Ibrutinib-associated cardiotoxicity
1/7/2023: 口服米诺地尔用于治疗化疗后的晚期脱发 Oral Minoxidil treating late alopecia following chemotherapy